+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Orphan Drug Evidence Requirements For Positive HTA Recommendations [workshop]
Home
Publications
Orphan Drug Evidence Requirements For Positive HTA Recommendations [workshop]
Back Home
Orphan Drug Evidence Requirements For Positive HTA Recommendations [workshop]
2015 ISPOR 18th Annual European Congress, November 7-11, 2015, Milan, Italy
Godfrey, J. | Meyer, F. | Toumi, M. | Bouslouk, M. |
Volume: , Issue: , Pages: ,
The website uses cookies.
Learn More
Ok
